Home
Clinical Resources Search
PQI: Epcoritamab (Epkinly®) for Relapsed/Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma

Epcoritamab (Epkinly®) for Relapsed/Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma

About this PQI

The purpose of this PQI is to discuss the clinical considerations of epcoritamab (Epkinly®) to optimize the outcomes for patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL).

How to Use a Positive Quality Intervention (PQI)

Essentially, it’s a tool to improve patient care by sharing best practices in oncology care. Consider this standardized, peer-review clinical guidance to oncology healthcare teams, enabling you and your team to consistently deliver high-quality care to your patients.

Find a PQI

Find Similar Resources

All Resources

PQI PQI in Action Treatment Support Kit Diffuse Large B-Cell Lymphoma (DLBCL) Follicular Lymphoma (FL) epcoritamab-bysp

PQI

Frequently Searched

Supported by

Epcoritamab (Epkinly®) for Relapsed/Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma

About this PQI

How to Use a Positive Quality Intervention (PQI)

Find Similar Resources

PQI: Eflapegrastim-xnst (Rolvedon) for Chemotherapy-Induced Neutropenia

PQI: Revumenib (Revuforj) for the Management of Acute Leukemia

PQI: Talectrectinib (Ibtrozi) for the Management of ROS1+ Advanced NSCLC

PQI: Zanidatamab-hrii (Ziihera) for the Management of Biliary Tract Cancer

PQI in Action: Abiraterone acetate (Yonsa®) Patient Selection and Management

PQI in Action: Enfortumab Vedotin-ejfv (Padcev®) and Pembrolizumab (Keytruda®) Management for Advanced or Metastatic Urothelial Carcinoma

PQI in Action: Fruquintinib (Fruzaqla®)

PQI in Action: Management of Tucatinib (Tukysa®) and Trastuzumab in HER2-Positive Metastatic Colorectal Cancer – 2

Treatment Support Kit: Elranatamab

Treatment Support Kit: Mirdametinib

Treatment Support Kit: Abemaciclib

Treatment Support Kit: Temozolomide

PQI: Advances in MRD Monitoring for Diffuse Large B-Cell Lymphoma (DLBCL)

PQI: Tafasitamab-cxix (Monjuvi®) for Relapsed/Refractory Diffuse Large B-Cell Lymphoma

PQI: Selinexor (Xpovio®) Patient Management

PQI: Loncastuximab tesirine-lpyl (Zynlonta®) in Relapsed/Refractory Large B-Cell Lymphoma

PQI: Tazemetostat (Tazverik®) Management in Relapsed/Refractory Follicular Lymphoma

PQI: Obinutuzumab (Gazyva®) for Chronic Lymphocytic Leukemia and Follicular Lymphoma

PQI: Initiating Mosunetuzumab-axgb (Lunsumio) in Relapsed/Refractory Follicular Lymphoma

PQI: Duvelisib (Copiktra®) for Chronic Lymphocytic Leukemia

Up Close with Epcoritamab

PQI: Eflapegrastim-xnst (Rolvedon) for Chemotherapy-Induced Neutropenia

S9 E4: Advancing Pharmacogenomics in Oncology

S9 E3: Firefighter Health & Cancer Prevention

PQI in Action: Abiraterone acetate (Yonsa®) Patient Selection and Management